The National Institute for Health and Care Excellence (NICE) has recommended Sogroya (somapacitan injection) for children aged 3 to 17 years with paediatric growth hormone deficiency.
The once-weekly treatment, developed by Novo Nordisk, offers an alternative to existing therapies for children experiencing growth failure due to the condition.
Growth hormone deficiency affects an estimated 1 in 3,500-4,000 children in the UK, where their bodies do not produce enough of the hormone naturally. Growth hormone, produced by the pituitary gland, is essential for normal growth during childhood…
